International Journal of Osteoarchaeology, Volume 0, Issue ja, -Not available-.
https://ift.tt/2QFEbV3
Αρχειοθήκη ιστολογίου
-
▼
2020
(289)
-
▼
Αυγούστου
(73)
-
▼
Αυγ 27
(17)
- Cancers
- High Altitude Medicine & Biology - Table of Cont...
- Eczema moisturizers: Allergenic Pote
- COVID‐19 und Auswirkungen auf dermatologische und...
- Asymptomatic chyluria presenting with fat-fl
- Evaluation of the Toxicity of Supernatant Culture...
- Biomedicine & Pharmacotherapy
- Dysphagia - Rehabilitation
-
▼
Αυγ 27
(17)
- ► Φεβρουαρίου (28)
-
▼
Αυγούστου
(73)
-
►
2019
(9071)
- ► Δεκεμβρίου (19)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (3642)
- ► Ιανουαρίου (3200)
-
►
2018
(39872)
- ► Δεκεμβρίου (3318)
- ► Σεπτεμβρίου (3683)
- ► Φεβρουαρίου (2693)
- ► Ιανουαρίου (3198)
-
►
2017
(41099)
- ► Δεκεμβρίου (3127)
- ► Σεπτεμβρίου (2173)
-
►
2016
(13807)
- ► Δεκεμβρίου (700)
- ► Σεπτεμβρίου (600)
- ► Φεβρουαρίου (1350)
- ► Ιανουαρίου (1400)
-
►
2015
(1500)
- ► Δεκεμβρίου (1450)
Ετικέτες
Τετάρτη 10 Οκτωβρίου 2018
Multiple myeloma bone lesions in skeletal remains: report of two known cases from the 20th century CAL Milano Cemetery Skeletal Collection
Τρίτη 9 Οκτωβρίου 2018
Full face ingenol mebutate for actinic keratosis: patient perspective
International Journal of Dermatology, EarlyView.
https://ift.tt/2CzrdFn
Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer
Abstract
Dendritic cell (DC)-based immunotherapies have been created for a broad expanse of cancers, and DC vaccines prepared with Wilms' tumor protein 1 (WT1) peptides have shown great therapeutic efficacy in these diseases. In this paper, we report the results of a phase I/II study of a DC-based vaccination for advanced breast, ovarian, and gastric cancers, and we offer evidence that patients can be effectively vaccinated with autologous DCs pulsed with WT1 peptide. There were ten patients who took part in this clinical study; they were treated biweekly with a WT1 peptide-pulsed DC vaccination, with toxicity and clinical and immunological responses as the principal endpoints. All of the adverse events to DC vaccinations were tolerable under an adjuvant setting. The clinical response was stable disease in seven patients. Karnofsky Performance Scale scores were enhanced, and computed tomography scans revealed tumor shrinkage in three of seven patients. Human leukocyte antigen (HLA)/WT1-tetramer and cytoplasmic IFN-γ assays were used to examine the induction of a WT-1-specific immune response. The immunological responses to DC vaccination were significantly correlated with fewer myeloid-derived suppressor cells (P = 0.045) in the pretreated peripheral blood. These outcomes offered initial clinical evidence that the WT1 peptide-pulsed DC vaccination is a potential treatment for advanced cancer.
https://ift.tt/2yaypnU
Intralesional pentoxifylline injection in localized alopecia areata
Journal of Cosmetic Dermatology, EarlyView.
https://ift.tt/2OeHIgD
Table of Contents
https://ift.tt/2OMT76G
Hypertensive Waist and Lipid Accumulation Product as Predictors of Metabolic Syndrome
Metabolic Syndrome and Related Disorders, Ahead of Print.
https://ift.tt/2ysCP8P